Company intelligence / Profile preview

Prometheus Biosciences

San Diego, California, USAprometheusbiosciences.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

In December 2022, Prometheus announced positive results from two Phase II studies of its lead candidate PRA023/MK‑7240 in ulcerative colitis and Crohn’s disease. The ARTEMIS‑UC trial was placebo-controlled for moderate-to-severely active UC; the APOLLO‑CD study was open-label for moderate-to-severe CD. Both showed promising safety and efficacy data presented at ECCO.[1][2][3]

No products were yet approved or commercialized at the time of acquisition.

The company was acquired by Merck & Co., Inc. in June 2023 for $10.8 billion.[1][2]

Therapeutic areas: GastroenterologyImmunologyRheumatology
Modalities: Monoclonal antibodies (mAbs)Small molecules (in pipeline)Companion diagnostics
Industry: Biotech

Partnerships

Acquired by Merck; no major external partnerships disclosed.

Beyond the preview

Go deeper on Prometheus Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prometheus Biosciences.